LC004905

2016 -- H 7662

STATE OF RHODE ISLAND

IN GENERAL ASSEMBLY

JANUARY SESSION, A.D. 2016

$A\ N\quad A\ C\ T$

RELATING TO BUSINESSES AND PROFESSIONS - PHARMACIES

Introduced By: Representative Raymond H. Johnston

Date Introduced: February 24, 2016

Referred To: House Health, Education & Welfare

It is enacted by the General Assembly as follows:

	R is charted by the General Assembly as follows.
1	SECTION 1. Sections 5-19.1-2 and 5-19.1-31 of the General Laws in Chapter 5-19.1
2	entitled "Pharmacies" are hereby amended to read as follows:
3	5-19.1-2. Definitions (a) "Board" means the Rhode Island board of pharmacy.
4	(b) "Change of ownership" means:
5	(1) In the case of a pharmacy, manufacturer, or wholesaler that is a partnership, any
6	change that results in a new partner acquiring a controlling interest in the partnership;
7	(2) In the case of a pharmacy, manufacturer, or wholesaler that is a sole proprietorship,
8	the transfer of the title and property to another person;
9	(3) In the case of a pharmacy, manufacturer, or wholesaler that is a corporation:
10	(i) A sale, lease exchange, or other disposition of all, or substantially all, of the property
11	and assets of the corporation; or
12	(ii) A merger of the corporation into another corporation; or
13	(iii) The consolidation of two (2) or more corporations resulting in the creation of a new
14	corporation; or
15	(iv) In the case of a pharmacy, manufacturer, or wholesaler that is a business
16	corporation, any transfer of corporate stock that results in a new person acquiring a controlling
17	interest in the corporation; or
18	(v) In the case of a pharmacy, manufacturer, or wholesaler that is a non-business
19	corporation, any change in membership that results in a new person acquiring a controlling vote

1 in the corporation.

2 (c) "Compounding" means the act of combining two (2) or more ingredients as a result 3 of a practitioner's prescription or medication order occurring in the course of professional practice 4 based upon the individual needs of a patient and a relationship between the practitioner, patient, 5 and pharmacist. Compounding does not mean the routine preparation, mixing, or assembling of drug products that are essentially copies of a commercially available product. Compounding shall 6 7 only occur in the pharmacy where the drug or device is dispensed to the patient or caregiver and 8 includes the preparation of drugs or devices in anticipation of prescription orders based upon 9 routine, regularly observed prescribing patterns.

(d) "Controlled substance" means a drug or substance, or an immediate precursor of such
drug or substance, so designated under or pursuant to the provisions of chapter 28 of title 21.

(e) "Deliver" or "delivery" means the actual, constructive, or attempted transfer from one
person to another of a drug or device, whether or not there is an agency relationship.

(f) "Device" means instruments, apparatus, and contrivances, including theircomponents, parts, and accessories, intended:

16 (1) For use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man17 or other animals; or

18 (2) To affect the structure or any function of the body of man or other animals.

19 (g) "Director" means the director of the Rhode Island state department of health.

(h) "Dispense" means the interpretation of a prescription or order for a drug, biological,
or device and, pursuant to that prescription or order, the proper selection, measuring,
compounding, labeling, or packaging necessary to prepare that prescription or order for delivery
or administration.

24 (i) "Distribute" means the delivery of a drug or device other than by administering or25 dispensing.

26 (j) "Drug" means:

27 (1) Articles recognized in the official United States Pharmacopoeia or the Official
28 Homeopathic Pharmacopoeia of the U.S.;

(2) Substances intended for use in the diagnosis, cure, mitigation, treatment, or
 prevention of disease in man, woman, or other animals;

31 (3) Substances (other than food) intended to affect the structure or any function of the
32 body of man, woman, or other animals; or

33 (4) Substances intended for use as a component of any substances specified in
34 subdivision (1), (2), or (3) of this subsection, but not including devices or their component parts

1 or accessories.

2 (k) "Equivalent and interchangeable" means having the same generic name, dosage form, and labeled potency, meeting standards of the United States Pharmacopoeia or National 3 4 Formulary, or their successors, if applicable, and not found in violation of the requirements of the 5 United States Food and Drug Administration, or its successor agency, or the Rhode Island department of health. 6

7

8

(1) "Intern" means:

(1) A graduate of an American Council on Pharmaceutical Education (ACPE)-accredited 9 program of pharmacy;

10 (2) A student who is enrolled in at least the first year of a professional ACPE-accredited 11 program of pharmacy; or

12 (3) A graduate of a foreign college of pharmacy who has obtained full certification from 13 the FPGEC (Foreign Pharmacy Graduate Equivalency Commission) administered by the National 14 Association of Boards of Pharmacy.

15 (m) "Limited function test" means those tests listed in the federal register under the 16 Clinical Laboratory Improvement Amendments of 1988 (CLIA) as waived tests. For the purposes 17 of this chapter, limited function test shall include only the following: blood glucose, hemoglobin 18 Alc, cholesterol tests, and/or other tests that are classified as waived under CLIA and are 19 approved by the United States Food and Drug Administration for sale to the public without a 20 prescription in the form of an over-the-counter test kit.

21 (n) "Legend drugs" means any drugs that are required by any applicable federal or state 22 law or regulation to be dispensed on prescription only or are restricted to use by practitioners 23 only.

24 (o) "Manufacture" means the production, preparation, propagation, compounding, or 25 processing of a drug or other substance or device or the packaging or repackaging.

26 (p) "Non-legend" or "nonprescription drugs" means any drugs that may be lawfully sold 27 without a prescription.

28 (q) "Person" means an individual, corporation, government, subdivision or agency, 29 business trust, estate, trust, partnership or association, or any other legal entity.

30 (r) "Pharmaceutical care" is the provision of drugs and other pharmaceutical services 31 intended to achieve outcomes related to cure or prevention of a disease elimination or reduction 32 of a patient's symptoms or arresting or slowing of a disease process. "Pharmaceutical care" 33 includes the judgment of a pharmacist in dispensing an equivalent and interchangeable drug or 34 device in response to a prescription after appropriate communication with the prescriber and the

1 patient.

(s) "Pharmacist in charge" means a pharmacist licensed in this state as designated by the
owner as the person responsible for the operation of a pharmacy in conformance with all laws and
regulations pertinent to the practice of pharmacy and who is personally in full and actual charge
of such pharmacy and personnel.

6 (t) "Pharmacy" means that portion or part of a premise where prescriptions are 7 compounded and dispensed, including that portion utilized for the storage of prescription or 8 legend drugs.

9 (u) "Pharmacy technician" means an individual who meets minimum qualifications 10 established by the board, that are less than those established by this chapter as necessary for 11 licensing as a pharmacist, and who works under the direction and supervision of a licensed 12 pharmacist.

13 (v) "Practice of pharmacy" means the interpretation, evaluation, and implementation of 14 medical orders; the dispensing of prescription drug orders; participation in drug and device 15 selection; the compounding of prescription drugs; drug regimen reviews and drug or drug-related 16 research; the administration of adult immunizations pursuant to a valid prescription or physician-17 approved protocol and in accordance with regulations, to include training requirements as 18 promulgated by the department of health; the administration of all forms of influenza 19 immunizations to individuals between the ages of nine (9) years and eighteen (18) years, 20 inclusive, pursuant to a valid prescription or prescriber-approved protocol, in accordance with the 21 provisions of § 5-19.1-31 and in accordance with regulations, to include necessary training 22 requirements specific to the administration of influenza immunizations to individuals between the 23 ages of nine (9) years and eighteen (18) years, inclusive, as promulgated by the department of 24 health; provision of patient counseling and the provision of those acts or services necessary to 25 provide pharmaceutical care; and/or the responsibility for the supervision for compounding and 26 labeling of drugs and devices (except labeling by a manufacturer, repackager, or distributor of 27 non-prescription drugs and commercially packaged legend drugs and devices), proper and safe 28 storage of drugs and devices, and maintenance of proper records for them; and the performance of 29 clinical laboratory tests, provided such testing is limited to limited-function tests as defined 30 herein. Nothing in this definition shall be construed to limit or otherwise affect the scope of 31 practice of any other profession.

32 (w) "Practitioner" means a physician, dentist, veterinarian, nurse, or other person duly
33 authorized by law in the state in which they practice to prescribe drugs.

34

(x) "Preceptor" means a pharmacist registered to engage in the practice of pharmacy in

- 1 this state who has the responsibility for training interns.
- 2 (y) "Prescription" means an order for drugs or devices issued by the practitioner duly 3 authorized by law in the state in which he or she practices to prescribe drugs or devices in the 4 course of his or her professional practice for a legitimate medical purpose.
- 5 (z) "Wholesaler" means a person who buys drugs or devices for resale and distribution to
 6 corporations, individuals, or entities other than consumers.
- 7

5-19.1-31. Administration of influenza immunizations to individuals between the

8 <u>ages of nine (9) years and eighteen (18) years, inclusive. --</u> Administration of immunizations

9 to individuals between the ages of nine (9) years and eighteen (18) years, inclusive. -- (a)

Parental consent shall be required for all pharmacist-administered immunizations for individualsunder the age of eighteen (18) years.

- (b) The department of health shall require a pharmacist who is authorized to administer influenza immunizations to individuals between the ages of nine (9) years and eighteen (18) years, inclusive, pursuant to § 5-19.1-2, to electronically report to the department all immunizations administered within seven (7) days of administration in the format and for the populations required by the department.
- 17 (c) (1) The department of health shall require a pharmacist who is authorized to 18 administer influenza immunizations to individuals between the ages of nine (9) years and 19 eighteen (18) years, inclusive, pursuant to § 5-19.1-2 to provide notification of a patient's 20 immunization to the patient's primary care provider, if known, within fourteen (14) days of 21 administration.

(2) The department of health's rules and regulations shall include provisions to ensure that the administering pharmacist make a good faith effort to obtain information relating to the identity of a patient's primary care provider or primary care practice, for the purposes of fulfilling the reporting requirements of subdivision (c)(1) herein. If a patient does not have an existing relationship with a primary care provider or primary care practice, the administering pharmacist shall proceed with the reporting requirements contained in subsection (b) herein.

28

SECTION 2. This act shall take effect upon passage.

LC004905

EXPLANATION

BY THE LEGISLATIVE COUNCIL

OF

AN ACT

RELATING TO BUSINESSES AND PROFESSIONS - PHARMACIES

This act would expand a pharmacist's immunization authority for individuals between the
 ages of nine (9) and eighteen (18) by permitting the administration of a broader array of vaccines.
 This act would take effect upon passage.

LC004905